A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...

CHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSINESS WIRE)--BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service ...

Acuitas’ LNP enabled delivery of three doses of a personalized CRISPR therapy with no adverse events to an infant patient with severe urea cycle disorder Athebody® DARPin-conjugated LNP resulted in ...

Authorization expands academic and industry researcher access for LNP delivery optimization, mRNA vaccine development and gene therapy research A new agreement between Promega Corporation and the RNA ...

The approval of messenger RNA (mRNA) based COVID-19 vaccines marked a pivotal scientific milestone, establishing mRNA as an innovative drug modality with immense therapeutic potential. However, due to ...

Findings show Mirai’s in vivo data-driven machine learning platform can optimize lipid nanoparticles for adipocyte delivery while reducing off-target delivery to liver and spleen Data highlight high ...

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ ...